Georgia Clinical Trials

A listing of Georgia clinical trials actively recruiting patient volunteers.

Filter by Condition
1906 trials found

Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow

NCT04594239

Confirm the effectiveness of Belotero Balance® (+) Lidocaine injection for the correction of volume loss in the infraorbital hollow (IOH) area by demonstrating superiority to untreated control Identify the incidence of adverse events (AEs) and serious adverse events (SAEs)

Conditions: Correction of Volume Loss in the Infraorbital Hollow Area
Phase: Not Applicable

IORT-Breast at MCNH

NCT04595435

Intraoperative Breast Radiation Therapy (IORT-Breast) utilizing the Xoft Axxent Electronic Brachytherapy System (Xoft) has been recently introduced as a treatment option for women 50 years of age and older who have early stage, low risk Invasive Breast Cancer (IBC). Clinical trials have shown IORT to be non-inferior to whole breast radiation, however some concern continues with rates of recurrence and clinical outcomes. Given the recent introduction and continued debate it is an excellent oppor ...

Conditions: Breast Cancer Female, Early-stage Breast Cancer

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419

This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).

Conditions: Macular Edema, Retinal Vein Occlusion

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT04592341

This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by change from baseline to Week 104 in brain amyloid positron emission tomography (PET). The administration of gantenerumab as a single injection of Q1W will be investigated in this study, to simplify the dosing regimen for participants.

Conditions: Alzheimer Disease

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

NCT04585724

This phase I trial studies the side effects of stereotactic radiosurgery with abemaciclib, ribociclib, or palbociclib in treating patients with hormone receptor positive breast cancer that has spread to the brain (brain metasteses). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Abemaciclib, ribociclib, and palbociclib may stop the growth of tumor cells by blocking some ...

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

Physiologic Signals and Signatures With the Accuryn Monitoring System (The Accuryn Registry)

NCT04585555

The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device . Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System. Analysis of these data has the potential to be able to acutely guide resuscitation and monitor trends for emerging critical conditions, as well as identify potential benefits and impac ...

Conditions: Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome, Cardiothoracic Surgery, Acute Respiratory Distress Syndrome (ARDS)

Big Effect Trial (BET-A) for the Treatment of COVID-19

NCT04583956

This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 40 sites throughout the US. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively la ...

Conditions: COVID-19

Oscillation and Lung Expansion Therapy in Patients With COVID-19

NCT04582214

This is a non-randomized prospective open-label cohort study in patients with COVID-19 who require intubation and mechanical ventilation.

Conditions: COVID-19, Oscillation and Lung Expansion, Ventilation
Phase: Not Applicable

HIV Treatment Adherence Dose Determination Trial

NCT04577313

The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.

Conditions: HIV Infections
Phase: Not Applicable

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder

NCT04567524

Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or less and thereby improving the management of schizophrenia. Study LYN-005-C-004 will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose administration of the ER formulation at two dose levels of LYN-005 relative to IR risperidone.

Conditions: Schizophrenia Schizoaffective

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04557046

Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.

Conditions: Covid19
Phase: Not Applicable

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

NCT04554914

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, Chronic Active Epstein-Barr Virus (CAEBV), Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH), Lymphohistiocytosis, Hemophagocytic